The global postoperative pain market is set to experience remarkable expansion, with projections indicating it will surpass USD 63.8 billion by 2033. This represents a substantial increase from its estimated value of USD 38.43 billion in 2023. The market is expected to grow at a robust compound annual growth rate (CAGR) of 5.2% throughout the forecast period.
Postoperative pain management involves a broad spectrum of pharmaceuticals and medical devices aimed at alleviating and controlling pain following surgical procedures. As postoperative pain continues to be a critical issue for patients undergoing surgery, effective pain management strategies have become more crucial than ever. These strategies not only enhance patient comfort but also accelerate recovery and improve overall clinical outcomes.
The surge in the postoperative pain market is driven by advancements in medical technology and pharmaceuticals. Innovations in pain management therapies, combined with an increasing number of surgical procedures globally, are fueling the demand for more efficient and effective pain relief solutions. The growing emphasis on patient-centric care and improved clinical outcomes further propels the need for advanced postoperative pain management strategies.
The projected market growth highlights the importance of continuous research and development in this essential field. Healthcare providers and industry stakeholders are encouraged to focus on creating and deploying innovative pain management solutions to meet the rising demand and elevate patient care on a global scale.
Key Takeaways from the Postoperative Pain Market:
- By 2022, the United States is predicted to hold 87.9% of the market for postoperative pain in North America. It is anticipated that the adoption of opioid treatment will slow the opioid epidemic’s spread across North America, especially in the United States.
- Germany is projected to account for 26.9% of the postoperative pain market in Europe in 2022.
- The postoperative pain market in South Korea is projected to expand at a 6.3% CAGR during the forecast period due to the nation’s rising surgical rate.
- Opioids are typically provided for postoperative pain in Japan, however, due to an increase in opioid use for non-medical purposes, regulating authorities are encouraging doctors to prescribe non-opioid drugs, which presents a chance for firms to introduce unique non-opioid drugs.
- The opioid drug class is expected to increase at a 4% CAGR throughout the projection period, accounting for a sizeable share of 61.3% in 2022.
- In terms of route of administration, oral postoperative pain is predicted to hold 37.8% of the market in 2022.
What is the Competition Scenario of the Postoperative Pain Market?
The main strategy used by major suppliers of postoperative pain medications for the development of new product lines of pain medications is the collaboration and acquisition of other pharmaceutical companies. As important stakeholders place more attention on the development of abuse-deterrent opioid medications and the introduction of extended-release non-opioid therapies for post-surgery pain, the demand for painkiller pharmaceuticals is rising. Similar to this, increased efforts to identify and commercialize non-narcotic drugs as well as raising public awareness of postoperative pain management are promoting market expansion.
Latest Developments in the Postoperative Pain Market:
- Assertio Therapeutics, Inc. was acquired by Zyla Life Sciences in May 2020. As a result, a growing commercial pharmaceutical company was able to increase the number of drugs it offered for treating pain, inflammation, and neurology.
- According to Heron Therapeutics, Inc., Health Canada announced in March 2022 the commercialization of ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia following bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty surgical procedures.
- In March 2022, a Phase IIb trial on the perioperative long-acting analgesic drug CPL-01 was completed, and Cali Biosciences Co., Ltd., a biopharmaceutical company specializing in the discovery and development of innovative pharmaceuticals, reported favorable findings.
Full Report on Postoperative Pain: Explore the Latest Trends and Insights in Our Detailed Analysis!
Key Players in the Postoperative Pain Industry:
- Novartis AG
- Allergan plc
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V
- Pfizer Inc.
- Purdue Pharma L.P
- Janssen Pharmaceuticals, Inc.
- Endo International plc
- Pacira Pharmaceuticals Inc.
- Egalet Corporation
- GlaxoSmithKline Plc.
Postoperative Pain Industry Survey by Category:
By Drug Class:
- Opioids
- NSAIDs
- Local Anesthetic
- Acetaminophen
By Route of Administration:
- Injectable
- Oral
- Topical
- Transdermal
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Clinics
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
